Date:10/31/2011

49,990$54,503Non-GAAP net incomeGAAP net income$30,828$39,257Restructuring and transformation costs8,8652,863Contingent consideration income(1,580)(1,894)Tax benefit associated with non-GAAP items(2,350)(1,067)Non-GAAP net income$35,763$39,159Non-GAAP net income per common share assuming dilutionGAAP net income per common share assuming dilution$1.18$1.54Non-GAAP items after tax per common share assuming dilution$0.19($0.00)Non-GAAP net income per common share assuming dilution$1.37$1.54Presented below are additional Constant Currency performance measures.  We measure different components of our business at constant currency.  We believe this information is useful for investors because it allows for an evaluation of the Company without the effect of changes in foreign exchange rates.  These results convert our local foreign currency operating results to the US Dollar at constant exchange rates of $1.20 per Euro, and 110 Yen to the $1.00.  They also exclude the results of our foreign currency hedging program described in Note 7 to our consolidated financial statements in our Form 10-K.  Non-GAAP revenuesGAAP revenue$350,014$329,872Foreign currency effects(24,607)(16,419)Non-GAAP revenue - constant currency$325,407$313,453Non-GAAP net incomeNon-GAAP net income, adjusted for restructuring, transformation costs and contingent consideration income$35,763$39,159Foreign currency effects(6,416)(7,087)Income tax associated with foreign currency effects1,8271,999Non-GAAP net income - constant currency31,17434,071Non-GAAP net income per common share assuming dilutionNon-GAAP net income per common share assuming dilution, adjusted for restructuring, transformation costs and contingent consideration income$1.37$1.54Foreign currency effects after tax per common share assuming dilution($0.18)($0.20)Non-GAAP net income per common share assuming dilution - constant currency$1.19$1.34CONTACT:
Gerry Gould, VP-Investor Relations
Tel. (781) 356-9402'/>"/>

SOURCE Haemonetics Corporation Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Related medicine technology :

1. Haemonetics Sets Date for Second Quarter Fiscal Year 2012 Earnings Release: October 31, 2011
2. Haemonetics Sets Date for Fourth Quarter Fiscal Year 2011 Earnings Release: May 2, 2011
3. Haemonetics to Present at J.P. Morgan Healthcare Conference
4. Fenwal Responds to New Lawsuit From Haemonetics; Reiterates Commitment to Blood Centers
5. Pacira Pharmaceuticals, Inc. Reports Third Quarter 2011 Financial Results
6. ReportsnReports - Hyper Acute Pancreas (Pancreatic Cancer) - Analysis and Forecasts to 2020
7. HeartWare International Reports Third Quarter 2011 Revenues of $21.3 Million; 54% Increase From $13.8 Million in Third Quarter 2010
8. Uroplasty Reports Fiscal Second Quarter 2012 Financial Results
9. Varian Medical Systems Reports Results for Fourth Quarter of Fiscal Year 2011
10. ERT Reports Third Quarter 2011 Operating Results
11. CryoLife Reports Financial Results for the Third Quarter and First Nine Months of 2011